In:
Clinical Transplantation, Wiley, Vol. 35, No. 9 ( 2021-09)
Abstract:
The coronavirus disease 2019 (COVID‐19) pandemic represents a major concern in immunosuppressed patients such as heart transplant recipients. Therefore, we performed a systematic review to summarize the clinical features, treatment, and outcomes of heart transplant recipients with COVID‐19. We searched electronic databases from inception to January 11, 2021. Thirty‐nine articles (22 case reports and 17 cohorts) involving 415 patients were included. The mean age was 59.9 ± 15.7 years and 77% of patients were men. In cohort studies including outpatients and inpatients, the hospitalization rate was 77%. The most common symptoms were fever (70%) and cough (67%). Inflammatory biomarkers (C‐reactive protein and procalcitonin) were above the normal range. Forty‐eight percent of patients presented with severe or critical COVID‐19. Hydroxychloroquine (54%), azithromycin (14%), and lopinavir/ritonavir (14%) were the most commonly used drugs. Forty‐nine percent of patients discontinued the baseline regimen of antimetabolites. In contrast, 59% and 73% continued the same regimen of calcineurin inhibitors and corticosteroids, respectively. Short‐term mortality among cohorts limited to inpatients was 25%. Our review suggests that heart transplant recipients with COVID‐19 exhibited similar demographic and clinical features to the general population. However, the prognosis was poor in these patients.
Type of Medium:
Online Resource
ISSN:
0902-0063
,
1399-0012
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
2739458-X
detail.hit.zdb_id:
2004801-4
Permalink
